Sparking curiosity among underprivileged students through hands-on STEM education.SAN FRANCISCO, June 9, 2026 /PRNewswire/ -- STEM education has become an increasingly important part of...
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with no required topicals from the startINDIANAPOLIS,...
Thousands of children, families, and communities will have the opportunity to learn to fish with national park rangers at more than 50 national parks.WASHINGTON,...
Investment represents RPC's fourth portfolio companyWESTERLY, R.I., June 9, 2026 /PRNewswire/ -- River Pines Capital (RPC), a private investment firm focused on scaling category-defining...
Child Creativity Lab STEAM workshop with Boys & Girls Clubs of Chicago cultivates design thinking skillsGenesis Inspiration Foundation awards $25,000 grant to Creative Netwerk...
Hyundai hosts free car seat safety event at Wilkins Hyundai as part of five‑year partnership focused on preventing child injuriesCHICAGO, June 9, 2026 /PRNewswire/...
Postal Service and Ralph Lauren dedicate American Icons in unveiling ceremonyNEW YORK, June 9, 2026 /PRNewswire/ -- The U.S. Postal Service today honored the...
LOS ANGELES, June 9, 2026 /PRNewswire/ -- As summer temperatures begin to climb across the United States, many households are placing greater emphasis on...
New Harris Poll research of more than 3,000 U.S. adults finds Eagle Scouts report 2x lower loneliness, significantly higher purpose and leadership and stronger...
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and sponsored by the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham
- Elraglusib will be assessed in combination with dinutuximab beta plus chemotherapy in patients with relapsed and refractory neuroblastoma
- Complete response in neuroblastoma patient achieved in Phase 1 study of elraglusib in refractory pediatric cancers
Special exhibition runs June 11–July 19 at Rockefeller Center in New York CityExhibition celebrates FIFA World Cup™ history through immersive experiences, innovation and Hyundai...
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026.